Dana-Farber registers Phase I/II trial of Tango's TNG462 with lorlatinib in ALK+ NSCLC
Investigator-sponsored study will test vopimetostat plus lorlatinib in MTAP-deleted, ALK-rearranged lung cancer patients who progressed on prior TKI therapy.
One new trial involving Tango Therapeutics was registered this week.
- A Phase I/II study called "TAP-ALK" testing Tango's TNG462 (vopimetostat) combined with lorlatinib was listed under NCT07938463, with Dana-Farber Cancer Institute as lead sponsor and Tango Therapeutics as a collaborator. The study is an investigator-sponsored interventional study of TNG462 (vopimetostat) in combination with lorlatinib for participants with MTAP-deleted, ALK-rearranged non-small cell lung cancer (NSCLC) following progression on prior tyrosine kinase inhibitor (TKI) therapy.1 The trial is being conducted under IND 183798 and plans to enroll 30 participants.1 Status is not yet recruiting, with an estimated start date of 2027-04-30. Primary outcomes include dose-limiting toxicity, maximum tolerated dose, and recommended Phase II dose, determined using a Backfill Bayesian Optimal Interval (BF-BOIN) design to determine the MTD of TNG462.1 Dosing will begin with TNG462 will start at 200 mg QD and may be escalated to 250 mg QD at the optional Dose Level 3 if Dose Level 2 is tolerated, at the discretion of the Sponsor-Investigator.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.